Evaxion Biotech reported that its AI‑Immunology platform achieved an 86% precision rate in selecting vaccine targets for its personalized cancer vaccine EVX‑01 in a Phase 2 trial, a figure that exceeds the precision rates of other methods. The data were presented at the AACR Annual Meeting in San Diego on April 22, 2026, following the announcement on April 17, 2026.
The Phase 2 study combined EVX‑01 with Merck’s KEYTRUDA® (pembrolizumab) in patients with advanced melanoma. The trial achieved a 75% objective response rate and an 86% de‑novo response rate, indicating the generation of new tumor‑specific T cells. Two‑year follow‑up showed durable vaccine‑specific immune responses, and a positive correlation was observed between the AI‑prediction scores and the magnitude of the immune response, underscoring the platform’s predictive power.
Evaxion’s results validate its proprietary AI‑Immunology platform and reinforce the company’s strategy to accelerate vaccine development across oncology and infectious disease indications. The high precision rate and strong clinical outcomes position Evaxion ahead of competitors that rely on conventional target‑selection methods. The company also highlighted the platform’s scalability for glioblastoma vaccines, suggesting a broader therapeutic reach. Additional clinical data for EVX‑01 are expected in the second half of 2026, which could further strengthen the company’s pipeline.
"We are delighted with the data demonstrating again the unique capabilities of AI‑Immunology™ in identifying and selecting relevant vaccine targets," said Bigitte Rønø, Chief Scientific Officer. "This holds great potential for improving vaccine efficacy, and we are looking forward to discussing the data with both scientific stakeholders and potential business partners at the AACR Annual Meeting."
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.